Zydus Lifesciences has received regulatory approval in China for its innovative drug Desidustat, a treatment designed to address renal anemia in patients suffering from chronic kidney disease (CKD). The approval from China’s National Medical Products Administration (NMPA) represents a significant milestone for the Indian pharmaceutical company as it expands its presence in one of the world’s largest healthcare markets. The drug will be commercialized through an exclusive licensing agreement with a subsidiary of China Medical System Holdings Ltd.